Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study has found. These biomarkers - known as DNA methylation profiles - also can predict if the cancer is going to recur and if that recurrence will remain localized to the prostate or, instead, spread to other organs...

More...